Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Cardiovascular Medicine
Erschienen in: Current Treatment Options in Cardiovascular Medicine 4/2017

01.04.2017 | Imaging (Q Truong, Section Editor)

Updates on Stress Imaging Testing and Myocardial Viability With Advanced Imaging Modalities

verfasst von: Sandeep S. Hedgire, MD, Michael Osborne, MD, Daniel J. Verdini, MD, Brian B. Ghoshhajra, MD, MBA

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Opinion statement

Non-invasive stress testing plays a key role in diagnosis and risk stratification in patients with coronary artery disease. Technical advances in CT, MRI, and PET have lead to increased utility of these modalities in myocardial perfusion imaging. The aim of the review is to provide a succinct update on CT, PET, and MRI for myocardial stress perfusion imaging.
Literatur
1.
Multimodality Writing Group for Stable Ischemic Heart Disease, Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Card Fail. 2014;20:65–90.CrossRef
2.
Al-Mallah M, Kwong RY. Clinical application of cardiac CMR. Rev Cardiovasc Med. 2009;10:134–41.PubMed
3.
Cortigiani L, Bigi R, Sicari R. Is viability still viable after the STICH trial? Eur Heart J Cardiovasc Imaging. 2012;13:219–26.CrossRefPubMed
4.
Yang DH, Kim Y-H, Roh J-H, Kang J-W, Han D, Jung J, et al. Stress myocardial perfusion CT in patients suspected of having coronary artery disease: visual and quantitative analysis-validation by using fractional flow reserve. Radiology. 2015;276:715–23.CrossRefPubMed
5.
Pontone G, Andreini D, Guaricci AI, Guglielmo M, Mushtaq S, Baggiano A, et al. Rationale and design of the PERFECTION (comparison between stress cardiac computed tomography PERfusion versus Fractional flow rEserve measured by Computed Tomography angiography In the evaluation of suspected cOroNary artery disease) prospective study. J Cardiovasc Comput Tomogr. 2016;10:330–4.CrossRefPubMed
6.
Yang DH, KimY-H, Roh JH, Kang J-W, Ahn J-M, Kweon J, et al. Diagnostic performance of on-site CT-derived fractional flow reserve versus CT perfusion. Eur Heart J Cardiovasc Imaging. 2016. doi:10.​1093/​ehjci/​jew094
7.
Magalhães TA, Kishi S, George RT, Arbab-Zadeh A, Vavere AL, Cox C, et al. Combined coronary angiography and myocardial perfusion by computed tomography in the identification of flow-limiting stenosis—the CORE320 study: an integrated analysis of CT coronary angiography and myocardial perfusion. J Cardiovasc Comput Tomogr. 2015;9:438–45.CrossRefPubMedPubMedCentral
8.
Truong QA, Knaapen P, Pontone G, Andreini D, Leipsic J, Carrascosa P, et al. Rationale and design of the dual-energy computed tomography for ischemia determination compared to “gold standard” non-invasive and invasive techniques (DECIDE-Gold): a multicenter international efficacy diagnostic study of rest-stress dual-energy computed tomography angiography with perfusion. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2015;22:1031–40.CrossRef
9.
Ladeiras-Lopes R, Bettencourt N, Ferreira N, Sampaio F, Pires-Morais G, Santos L, et al. CT myocardial perfusion and coronary CT angiography: influence of coronary calcium on a stress-rest protocol. J Cardiovasc Comput Tomogr. 2016;10:215–20.CrossRefPubMed
10.
Ghoshhajra BB, Maurovich-Horvat P, Techasith T, Medina HM, Verdini D, Sidhu MS, et al. Infarct detection with a comprehensive cardiac CT protocol. J Cardiovasc Comput Tomogr. 2012;6:14–23.CrossRefPubMed
11.
Dorbala S, Di Carli MF, Delbeke D, Abbara S, DePuey EG, Dilsizian V, et al. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med Off Publ Soc Nucl Med. 2013;54:1485–507.
12.
13.
Sciagrà R, Passeri A, Bucerius J, Verberne HJ, Slart RHJA, Lindner O, et al. Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging. 2016;43:1530–45.CrossRefPubMed
14.
Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol. 1990;15:1032–42.CrossRefPubMed
15.
Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med Off Publ Soc Nucl Med. 1996;37:1701–12.
16.
Naya M, Murthy VL, Taqueti VR, Foster CR, Klein J, Garber M, et al. Preserved coronary flow reserve effectively excludes high-risk coronary artery disease on angiography. J Nucl Med Off Publ Soc Nucl Med. 2014;55:248–55.
17.
Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124:2215–24.CrossRefPubMedPubMedCentral
18.
Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131:19–27.CrossRefPubMed
19.
Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. Circ Cardiovasc Imaging. 2012;5:700–7.CrossRefPubMed
20.
Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol. 2001;26:147–86.CrossRefPubMed
21.
Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, et al. Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med Off Publ Soc Nucl Med. 2010;51:1592–9.
22.
Stabin MG. Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk. J Nucl Med Off Publ Soc Nucl Med. 2008;49:1555–63.
23.
Shah NR, Charytan DM, Murthy VL, Skali Lami H, Veeranna V, Cheezum MK, et al. Prognostic value of coronary flow reserve in patients with dialysis-dependent ESRD. J Am Soc Nephrol JASN. 2016;27:1823–9.CrossRefPubMed
24.
Van Tosh A, Votaw JR, Cooke CD, Reichek N, Palestro CJ, Nichols KJ. Relationships between left ventricular asynchrony and myocardial blood flow. J Nucl Cardiol. 2017;24(1):43–52.
25.
Legallois D, Belin A, Nesterov SV, Milliez P, Parienti J-J, Knuuti J, et al. Cardiac rehabilitation improves coronary endothelial function in patients with heart failure due to dilated cardiomyopathy: a positron emission tomography study. Eur J Prev Cardiol. 2016;23:129–36.CrossRefPubMed
26.
Christensen TE, Ahtarovski KA, Bang LE, Holmvang L, Søholm H, Ghotbi AA, et al. Basal hyperaemia is the primary abnormality of perfusion in Takotsubo cardiomyopathy: a quantitative cardiac perfusion positron emission tomography study. Eur Heart J Cardiovasc Imaging. 2015;16:1162–9.CrossRefPubMed
27.
Knudsen A, Christensen TE, Ghotbi AA, Hasbak P, Lebech A-M, Kjær A, et al. Normal myocardial flow reserve in HIV-infected patients on stable antiretroviral therapy: a cross-sectional study using rubidium-82 PET/CT. Medicine (Baltimore). 2015;94:e1886.CrossRef
28.
Valenta I, Antoniou A, MarashdehW, Leucker T, Kasper E, Jones SR, et al. PET-measured longitudinal flow gradient correlates with invasive fractional flow reserve in CAD patients. Eur Heart J Cardiovasc Imaging. 2016. doi:10.​1093/​ehjci/​jew116
29.
Dey D, Diaz Zamudio M, Schuhbaeck A, Juarez Orozco LE, Otaki Y, Gransar H, et al. Relationship between quantitative adverse plaque features from coronary computed tomography angiography and downstream impaired myocardial flow reserve by 13N-ammonia positron emission tomography: a pilot study. Circ Cardiovasc Imaging. 2015;8:e003255.CrossRefPubMedPubMedCentral
30.
Assante R, Zampella E, Arumugam P, Acampa W, Imbriaco M, Tout D, et al. Quantitative relationship between coronary artery calcium and myocardial blood flow by hybrid rubidium-82 PET/CT imaging in patients with suspected coronary artery disease. J Nucl Cardiol. 2016. doi:10.​1007/​s12350-015-0359-1
31.
Bulluck H, White SK, Fröhlich GM, Casson SG, O’Meara C, Newton A, et al. Quantifying the area at risk in reperfused ST-segment-elevation myocardial infarction patients using hybrid cardiac positron emission tomography-magnetic resonance imaging. Circ Cardiovasc Imaging. 2016;9:e003900.CrossRefPubMedPubMedCentral
32.
Suda M, Onoguchi M, Tomiyama T, Ishihara K, Takahashi N, Sakurai M, et al. The reproducibility of time-of-flight PET and conventional PET for the quantification of myocardial blood flow and coronary flow reserve with (13)N-ammonia. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2016;23:457–72.CrossRef
33.
Presotto L, Busnardo E, Perani D, Gianolli L, Gilardi MC, Bettinardi V. Simultaneous reconstruction of attenuation and activity in cardiac PET can remove CT misalignment artifacts. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2016;23:1086–97.CrossRef
34.
Slomka PJ, Diaz-Zamudio M, Dey D, Motwani M, Brodov Y, Choi D, et al. Automatic registration of misaligned CT attenuation correction maps in Rb-82 PET/CT improves detection of angiographically significant coronary artery disease. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2015;22:1285–95.CrossRef
35.
Hunter CRRN, Klein R, Beanlands RS, DeKemp RA. Patient motion effects on the quantification of regional myocardial blood flow with dynamic PET imaging. Med Phys. 2016;43:1829.CrossRefPubMed
36.
Ahmed MAA, Xiao P, Xie Q. New approach for simultaneous respiratory and cardiac motion correction in cardiac PET (NAMC-CPET). Phys Med Biol. 2015;60:7779–804.CrossRefPubMed
37.
Klén R, Noponen T, Koikkalainen J, Lötjönen J, Thielemans K, Hoppela E, et al. Evaluation of motion-correction methods for dual-gated cardiac positron emission tomography/computed tomography imaging. Nucl Med Commun. 2016;37:956–68.CrossRefPubMed
38.
Monmeneu Menadas JV, Lopez-Lereu MP, Estornell Erill J, Garcia Gonzalez P, Igual Muñoz B, Maceira GA. Pharmacological stress cardiovascular magnetic resonance: feasibility and safety in a large multicentre prospective registry. Eur Heart J Cardiovasc Imaging. 2016;17:308–15.CrossRefPubMed
39.
Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet Lond Engl. 2012;379:453–60.CrossRef
40.
de Jong MC, Genders TSS, van Geuns R-J, Moelker A, Hunink MGM. Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: a systematic review and meta-analysis. Eur Radiol. 2012;22:1881–95.CrossRefPubMedPubMedCentral
41.
Heydari B, Juan Y-H, Liu H, Abbasi S, Shah R, Blankstein R, et al. Stress perfusion cardiac magnetic resonance imaging effectively risk stratifies diabetic patients with suspected myocardial ischemia. Circ Cardiovasc Imaging. 2016;9:e004136.PubMedPubMedCentral
42.
Kim RJ, Albert TSE, Wible JH, Elliott MD, Allen JC, Lee JC, et al. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation. 2008;117:629–37.CrossRefPubMed
43.
Ibrahim T, Bülow HP, Hackl T, Hörnke M, Nekolla SG, Breuer M, et al. Diagnostic value of contrast-enhanced magnetic resonance imaging and single-photon emission computed tomography for detection of myocardial necrosis early after acute myocardial infarction. J Am Coll Cardiol. 2007;49:208–16.CrossRefPubMed
44.
Pegg TJ, Selvanayagam JB, Jennifer J, Francis JM, Karamitsos TD, Dall’Armellina E, et al. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:56.CrossRefPubMedPubMedCentral
45.
Buss SJ, Krautz B, Hofmann N, Sander Y, Rust L, Giusca S, et al. Prediction of functional recovery by cardiac magnetic resonance feature tracking imaging in first time ST-elevation myocardial infarction. Comparison to infarct size and transmurality by late gadolinium enhancement. Int J Cardiol. 2015;183:162–70.CrossRefPubMed
46.
Wu KC, Kim RJ, Bluemke DA, Rochitte CE, Zerhouni EA, Becker LC, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol. 1998;32:1756–64.CrossRefPubMed
47.
Wu KC. CMR of microvascular obstruction and hemorrhage in myocardial infarction. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2012;14:68.
48.
van Gaal WJ, Banning AP. Percutaneous coronary intervention and the no-reflow phenomenon. Expert Rev Cardiovasc Ther. 2007;5:715–31.CrossRefPubMed
49.
Jerosch-Herold M. Quantification of myocardial perfusion by cardiovascular magnetic resonance. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2010;12:57.CrossRef
50.
Coelho-Filho OR, Rickers C, Kwong RY, Jerosch-Herold M. MR myocardial perfusion imaging. Radiology. 2013;266:701–15.CrossRefPubMed
51.
Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging. 2002;18:539–42.PubMed
52.
Gupta A, Lee VS, Chung Y-C, Babb JS, Simonetti OP. Myocardial infarction: optimization of inversion times at delayed contrast-enhanced MR imaging. Radiology. 2004;233:921–6.CrossRefPubMed
53.
Jimenez Juan L, Crean AM, Wintersperger BJ. Late gadolinium enhancement imaging in assessment of myocardial viability: techniques and clinical applications. Radiol Clin North Am. 2015;53:397–411.CrossRefPubMed
54.
Yun C-H, Tsai J-P, Tsai C-T, Mok GSP, Sun J-Y, Hung C-L, et al. Qualitative and semi-quantitative evaluation of myocardium perfusion with 3 T stress cardiac MRI. BMC Cardiovasc Disord. 2015;15:164.CrossRefPubMedPubMedCentral
55.
Heydari B, Kwong RY, Jerosch-Herold M. Technical advances and clinical applications of quantitative myocardial blood flow imaging with cardiac MRI. Prog Cardiovasc Dis. 2015;57:615–22.CrossRefPubMed
56.
Sharif B, Dharmakumar R, LaBounty T, Arsanjani R, Shufelt C, Thomson L, et al. Towards elimination of the dark-rim artifact in first-pass myocardial perfusion MRI: removing Gibbs ringing effects using optimized radial imaging: toward elimination of dark-rim artifacts in first-pass perfusion CMR. Magn Reson Med. 2014;72:124–36.CrossRefPubMed
57.
Sharif B, Arsanjani R, Dharmakumar R, Bairey Merz CN, Berman DS, Li D. All-systolic non-ECG-gated myocardial perfusion MRI: feasibility of multi-slice continuous first-pass imaging. Magn Reson Med. 2015;74:1661–74.CrossRefPubMedPubMedCentral
58.
Bi X, Wei J, Yang H-J, Dharmakumar R, Arsanjani R, et al. First-pass myocardial perfusion MRI with reduced subendocardial dark-rim artifact using optimized Cartesian sampling. J Magn Reson Imaging JMRI. 2017;45(2):542–55.
59.
Manisty C, Ripley DP, Herrey AS, Captur G, Wong TC, Petersen SE, et al. Splenic switch-off: a tool to assess stress adequacy in adenosine perfusion cardiac MR imaging. Radiology. 2015;276:732–40.CrossRefPubMed
60.
Shin T, Nayak KS, Santos JM, Nishimura DG, Hu BS, McConnell MV. Three-dimensional first-pass myocardial perfusion MRI using a stack-of-spirals acquisition. Magn Reson Med. 2013;69:839–44.CrossRefPubMed
61.
Raman SV, Dickerson JA, Mazur W, Wong TC, B Schelbert E, Min JK, et al. Diagnostic performance of treadmill exercise cardiac magnetic resonance: the prospective, multicenter exercise CMR’s accuracy for cardiovascular stress testing (EXACT) trial. J Am Heart Assoc. 2016;5(8): e003811.
62.
Dilsizian V. Cardiac magnetic resonance versus SPECT: are all noninfarct myocardial regions created equal? J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2007;14:9–14.CrossRef
63.
Rischpler C, Dirschinger RJ, Nekolla SG, Kossmann H, Nicolosi S, Hanus F, et al. Prospective evaluation of 18F-fluorodeoxyglucose uptake in postischemic myocardium by simultaneous positron emission tomography/magnetic resonance imaging as a prognostic marker of functional outcome. Circ Cardiovasc Imaging. 2016;9:e004316.PubMedPubMedCentral
Metadaten
Titel
Updates on Stress Imaging Testing and Myocardial Viability With Advanced Imaging Modalities
verfasst von
Sandeep S. Hedgire, MD
Michael Osborne, MD
Daniel J. Verdini, MD
Brian B. Ghoshhajra, MD, MBA
Publikationsdatum
01.04.2017
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 4/2017
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-017-0525-7

Weitere Artikel der Ausgabe 4/2017

Current Treatment Options in Cardiovascular Medicine 4/2017 Zur Ausgabe

Heart Failure (W Tang, Section Editor)

Targeting Frailty in Heart Failure

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Management of Percutaneous Coronary Intervention Complications

Vascular Disease (I Weinberg, Section Editor)

Novel and Advanced Techniques for Complex IVC Filter Retrieval

Cardio-oncology (M Fradley, Section Editor)

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia

Regenerative Medicine and Stem-cell Therapy (S Wu and P Hsieh, Section Editors)

Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy

Heart Failure (W Tang, Section Editor)

Targeting the Microbiome in Heart Failure

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise